Navigation Links
EYLEA™ (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
Date:6/28/2011

ubmitted for marketing approval for the treatment of wet AMD in the U.S. in February 2011 by Regeneron and in Europe in June 2011 by Bayer HealthCare.

Bayer HealthCare will market EYLEA™ outside the United States, where the companies will share equally the profits from any future sales of EYLEA.  Regeneron maintains exclusive rights to EYLEA in the United States.

About the VIEW Program

The VIEW (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) program consists of two randomized, double-masked, Phase 3 clinical trials evaluating EYLEA™ in the treatment of the neovascular form of age-related macular degeneration (wet AMD).  The VIEW 1 study, which randomized 1,217 patients, is being conducted in the United States and Canada by Regeneron under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration.  The VIEW 2 study, which randomized 1,240 patients, is being conducted in Europe, Asia Pacific, Japan, and Latin America by Bayer HealthCare.  The study designs are essentially identical.  The primary endpoint evaluation was conducted at 52 weeks.

In each of the studies, EYLEA was evaluated for its effect on maintaining and improving vision when dosed as an intravitreal injection on a schedule of 0.5 mg monthly, 2 mg monthly, or 2 mg every two months (following three monthly loading doses), as compared with intravitreal ranibizumab administered 0.5 mg every month during the first year of the studies.  As-needed (PRN) dosing with both agents, with a dose administered at least every three months (but not more often than monthly), is being evaluated during the second year of each study.

About EYLEA

EYLEA is a fully human fusion protein, consisting of portions of VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  EYLEA is a specific and highly potent blocker of these growth fac
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
2. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
3. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
4. Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation
5. Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
8. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
9. Reverse NanoJapan: Rice to host 25-30 Japanese students
10. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
11. Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer ... cosmetics, and other markets, announced today that it has ... qualified private investors led by Novit L.P., an investment ... transaction involved the signing of a Securities Purchase Agreement ... Stock at a price per share of $1.00, resulting ...
(Date:7/22/2014)... Lake, Wisconsin (PRWEB) July 22, 2014 ... be in attendance at the 2014 NCSL International ... Booth #423 will feature CONDEC pressure instrumentation, ... style weights, and the new, customized sets, Essential ... ago to promote cooperative efforts in solving the ...
(Date:7/22/2014)... 22, 2014 Two new members were ... Directors at its annual Shareholders Meeting on June 13: ... of The PFM Group, and Stephen T. Zarrilli, President ... announced the election of Michael A. DiPiano, Managing General ... and Richard P. Jaffe, Esq., of Duane Morris LLP, ...
(Date:7/22/2014)... 2014  Neogen Corporation (NASDAQ: NEOG ) ... which ended May 31, increased 19% from the previous ... compared to the prior year,s $27,190,000. Adjusted for a ... share in the current year were $0.76, compared to ... for the 2014 fiscal year established new all-time highs ...
Breaking Biology Technology:CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2Two New Members Elected to University City Science Center Board of Directors 2Two New Members Elected to University City Science Center Board of Directors 3Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8
... cadmium and selenium degrade in soil, unleashing toxic cadmium ... Buffalo study has found. The research, accepted for ... , demonstrates the importance of learning more about how ... the environment after disposal, said Diana Aga, the chemistry ...
... Champions Oncology, Inc., formerly Champions Biotechnology, Inc. (OTC: CSBR) ... appeared in Hebrew in the Israeli biotechnology business press ... 16, 2011: "Recently, a Hebrew language business ... a subsidiary which will be used by Champions for ...
... July 18, 2011 , 90% , ... Viral Load,Demonstrated Compared With Normal Disease Progression ... that it has completed a Phase Ib/II,clinical trial of its ... in viral count in HIV-infected,people compared with the placebo group, after ...
Cached Biology Technology:Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 2Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 3Champions Oncology Clarifies Misstatements in News Article 2Champions Oncology Clarifies Misstatements in News Article 3Champions Oncology Clarifies Misstatements in News Article 4SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 2SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 4SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 5SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 6
(Date:7/23/2014)... has the nasty habit of getting tangled and forming ... and learn how to disentangle them (e.g. useful for ... School for Advanced Studies (SISSA) in Trieste and his ... simulate these knots and their dynamics. In their latest ... , Micheletti together with Marco Di Stefano, first author ...
(Date:7/23/2014)... is available in German . ... modalities for orientation, some of which might be very ... the polarization pattern produced by sunlight in the atmosphere ... Max Planck Institute for Ornithology in Seewiesen, Germany, and ... that a night active mammal, the greater mouse-eared bat, ...
(Date:7/23/2014)... Currently, no cure exists for Alzheimer,s disease, the ... Americans. But scientists are now reporting new progress ... cancer treatment, that shows promise as a potential ... ACS, Journal of Medicinal Chemistry . , ... that in a healthy brain, the protein known ...
Breaking Biology News(10 mins):Bats use the evening sky's polarization pattern for orientation 2
... Center have identified how nanoparticles from diesel exhaust damage lung ... for people susceptible to airway disease. The scientists ... the genetic make-up of the affected individual. "We ... in polluted areas and why others don,t," said lead author ...
... young people engage in, has associated adverse health risks ... controlling overall alcohol usage, states an editorial in ... link only) http://www.cmaj.ca/embargo/cmaj110029.pdf . "Given the many ... we need a national strategy for controlling overall alcohol ...
... eating a big breakfast help weight loss or is ... confusing but new research published in BioMed Central,s open ... through these apparently contradictory reports. Dr Volker Schusdziarra, ... study on over 300 people who were asked to ...
Cached Biology News:Findings on pollution damage to human airways could yield new therapies 2
...
From formula-fed bovine calves Sterile, Cell culture tested...
Collected at a certified USDA establishment located within the United States. All final processing is done by Quad Five employees....
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
Biology Products: